Axovant's lead Alzheimer's drug flops in PhIII, ending an unlikely quest
Vivek Ramaswamy burst onto the biotech scene a few years ago with a brash plan to grab a failed drug from GlaxoSmithKline and hustle it straight into a pivotal Phase III study for Alzheimer’s — a disease that has defeated every pivotal shot taken at it over the past 15 years.
But intepirdine, like every other Phase III Alzheimer’s study, failed. And this failure for Ramaswamy’s Axovant will likely kill 5HT6 as a target in Alzheimer’s after several other studies with the same target also flopped over the past year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
